Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALFA-9802: GM-CSF Priming and Consolidation in AML
NCT00880243Phase 3Completed
- Sponsor
- Acute Leukemia French Association
- Start
- Mar 1999
- Primary completion
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of sargramostim in acute myeloid leukemia (AML), sponsored by Acute Leukemia French Association. Started Mar 1999; status: completed.
02
Drugs
sargramostim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00880243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00880243.